ESMO Open shared the post on X:

“Exploratory analysis on elderly (>65yrs) patients enrolled in JAVELINBladder100 trial in ESMO Open.

Efficacy & tolerability of maintenance avelumab confirmed with increased quality-adjusted time w/o symptoms/toxicity.”

Shilpa Gupta, Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic, reshared the post on X, adding:

“Happy to share our exploratory analysis on safety & tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial.

No new safety signals, efficacy well maintained in this subgroup.

Avelumab 1L maintenance prolonged OS versus BSC alone Quality-adjusted time without symptoms or toxicity was 4.57 months longer with avelumab versus BSC alone.”

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

Authors: Shilpa Gupta, et al.

Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial